Skip to main navigation

Careers
Investors & Media
Contact

SCIENCE
PIPELINE
DISEASE FOCUS
HAE COMMUNITY
CLINICAL TRIALS
ABOUT US

Events

Investor Menu

IR Nav

Overview
News & Events
News Releases Events Publications
Financials
SEC Filings Quarterly Results
Stock
Stock Performance Analyst Coverage
Corporate Governance
Governance Documents Leadership Board of Directors Committee Composition
Resources
Investor FAQs Contact Us Email Alerts

Past Events

Dec 7 - Dec 9, 2023

GA²LEN UCARE Conference 2023

Dec 6, 2023 8:00 AM EST

CHAPTER-1 Phase 2 Top-line Data

Click for Webcast

Supporting Materials

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks 177 KB

CHAPTER-1 Phase 2 Top-line Data Presentation 1.3 MB

Nov 9 - Nov 13, 2023

ACAAI 2023 Annual Scientific Meeting

Supporting Materials

Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks’ manifestations 207.4 KB

Riedl Audio Recording 7 MB

Understanding the reasons not to treat all HAE attacks and satisfaction for on-demand treatment: physician- and patient-reported data 266.5 KB

Mendivil Audio Recording 5 MB

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

Oct 23 - Oct 26, 2023

APAAACI 2023 International Conference

Supporting Materials

Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule for Treatment of HAE Attacks: Phase 2 Results 1.3 MB

Oct 13 - Oct 14, 2023

CIIC Fall 2023 Conference

Supporting Materials

Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial 4.4 MB

Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule in patients with hereditary angioedema attacks 2.7 MB

Sep 26, 2023 from 2:10 PM to 2:40 PM EDT

2023 Cantor Global Healthcare Conference

Click for Webcast

Sep 14 - Sep 16, 2023

18th German Allergy Congress

Supporting Materials

Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks (German) à link to Magerl 395.9 KB

Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial (German) à link to Aygoren 484.3 KB

Sep 11, 2023 3:35 PM EDT

Morgan Stanley 21st Annual Global Healthcare Conference

Click for Webcast

Sep 1 - Sep 3, 2023

HAEi Regional Conference EMEA

Supporting Materials

Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks 1 MB

Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary 319.2 KB

Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial 1 MB

Jul 20 - Jul 23, 2023

U.S. HAEA National Summit

Supporting Materials

Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial 1.8 MB

Treatment with oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule improves hereditary angioedema attack symptoms 1 MB

Pagination

Current page 1
Page 2
Page 3
…
Next page
Last page

Presentations

Corporate Presentation

FOLLOW US

©2023 Pharvaris N.V. © All Rights Reserved

Privacy Policy
Terms of Use